Limitations
CKD, kidney disease
KIDNEY DISEASE
The present study is a retrospective single-center study; thus, the causal relationship between the initial eGFR dip and other clinical comorbidities is unknown and there is a confounding by indication bias. It is also undeniable that clinical background of the enrolled patients is slightly different from a representative population of CKD patients without DM. The protective effect of SGLT2i against kidney disease was not evaluated due to short duration of the present study. Therefore, a longitudinal multicenter prospective study must be required to determine whether SGLT2i elicits its reno-protective effect through an initial eGFR dip in CKD patients without DM.